KEXING BIOPHARM revenue breakdown overview

KEXING BIOPHARM revenue for the last year amounted to 1.26 B CNY, the most of which — 608.06 M CNY — came from its highest performing source at the moment, Eprodin, the year earlier bringing 721.54 M CNY. The greatest contribution to the revenue figure was made by China — last year it brought KEXING BIOPHARM 1.26 B CNY, and the year before that — 1.32 B CNY.